Q3 2024 EPS Estimates for Option Care Health, Inc. Lowered by Analyst (NASDAQ:OPCH)

Option Care Health, Inc. (NASDAQ:OPCH) – Stock analysts at William Blair reduced their Q3 2024 EPS estimates for Option Care Health in a research report issued on Wednesday, April 24th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of $0.31 for the quarter, down from their previous forecast of $0.32. The consensus estimate for Option Care Health’s current full-year earnings is $1.17 per share. William Blair also issued estimates for Option Care Health’s Q4 2024 earnings at $0.35 EPS.

Option Care Health (NASDAQ:OPCH) last released its earnings results on Tuesday, April 23rd. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.22 by $0.04. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The business had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the business earned $0.21 earnings per share. The business’s quarterly revenue was up 12.8% on a year-over-year basis.

Several other analysts have also commented on OPCH. Barrington Research reissued an “outperform” rating and set a $38.00 target price on shares of Option Care Health in a research note on Wednesday. Jefferies Financial Group increased their target price on shares of Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, March 4th.

Option Care Health Stock Down 2.1 %

OPCH stock opened at $29.29 on Friday. Option Care Health has a 12 month low of $24.23 and a 12 month high of $35.74. The firm has a market cap of $5.09 billion, a PE ratio of 19.27, a P/E/G ratio of 1.65 and a beta of 1.22. The firm has a 50 day simple moving average of $32.04 and a 200 day simple moving average of $31.50. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.77 and a quick ratio of 1.33.

Institutional Investors Weigh In On Option Care Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPCH. Principal Securities Inc. purchased a new stake in Option Care Health in the 4th quarter worth approximately $27,000. Parallel Advisors LLC lifted its position in Option Care Health by 130.2% in the 4th quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock worth $28,000 after buying an additional 478 shares in the last quarter. TFO Wealth Partners LLC lifted its position in Option Care Health by 24,625.0% in the 4th quarter. TFO Wealth Partners LLC now owns 989 shares of the company’s stock worth $33,000 after buying an additional 985 shares in the last quarter. First Horizon Advisors Inc. purchased a new stake in Option Care Health in the 3rd quarter worth approximately $37,000. Finally, Park Place Capital Corp lifted its position in Option Care Health by 48.4% in the 1st quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock worth $38,000 after buying an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Insider Activity at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of Option Care Health stock in a transaction that occurred on Monday, February 26th. The stock was acquired at an average price of $31.55 per share, for a total transaction of $1,104,250.00. Following the transaction, the director now owns 269,528 shares in the company, valued at $8,503,608.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.64% of the stock is owned by insiders.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.